3 Result: Inventiva
Inventiva: Promising Lanifibranor Trial Data; Bullish View Towards 89bio, BRP, CompoSecure
June 13th, 2023
Inventiva S.A. (Nasdaq: IVA), a pharmaceutical company, has announced encouraging results from a Phase II clinical trial evaluating lanifibranor in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2D). Th. Read more
Akebia Therapeutics, MDxHealth, Avis Budget, argenx, Five9, Inventiva: Analyst Upgrades and Initiations Point to Potential Upsides
May 31st, 2023
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company, received an upgrade from Neutral to Overweight by Piper Sandler, with the price target raised from $2 to $4. On Wednesday, $AKBA closed at $1.04, indicating a potential u. Read more
Upgraded Rating for The Gap, First Commonwealth Financial, Wendy's, MaxLinear, and Inventiva
May 20th, 2023
The Gap, Inc. (NYSE: GPS) received an upgrade from Sell to Neutral by Citigroup, a notable financial institution. This upgrade suggests a shift in sentiment towards the company. On Friday, $GPS closed at $7.78, experiencing a decline of $0.33 (-4.07%. Read more
Want To Find Some News?
News By Industries
Recent Post
-
DOT, DoW, DHS Join Forces to Protect Southern Border Airspace
October 16th, 2026FTC Sues Ticket Broker Over Unlawful Tactics Used to Buy Millions of Tickets to Popular Live Events
October 15th, 2026October 15th, 2026FDA Approves First Treatment for Certain People With BCG-Unresponsive Bladder Cancer
October 14th, 2026U.S. Treasury Announces Record Enforcement Actions Against Bank of America
October 14th, 2026
Member Login